Stockreport

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 [Yahoo! Finance]

Centessa Pharmaceuticals plc - American Depositary Shares  (CNTA) 
PDF Orexin Agonist Program: Clinical proof-of-concept data for ORX750 in sleep-deprived healthy volunteers planned in 2024 LockBody ® Technology Platform: Ongoing Phase 1 [Read more]